Online Only Articles

Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu
Department of Hematology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital; Key Laboratory of Hematology of Nanjing Medical University; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Vol. 105 No. 1 (2020): January, 2020 https://doi.org/10.3324/haematol.2019.220301